urinaemia
Conditions
Interventions
Experimental group:On the basis of conventional peritoneal dialysis, oral urine clearance granule treatment, treatment cycle: 24W (including 2W lead-in period)
Non-constipation control group on peritoneal dialysis:Routine peritoneal dialysis
Healthy controls:not
Sponsors
And Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age: 18~75, with no limit on gender or nationality; (2) For ESRD patients receiving regular peritoneal dialysis for more than 3 months, and the dialysis regimen remained unchanged during the trial; (3) Patients diagnosed with constipation according to the diagnostic criteria of Rome; (4) According to the Bristol fecal trait scale, the stool trait type is 1,2 and 3; (5) The subject was informed and voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Known allergy to Niaoduqing granules; (2) People who are prone to diarrhea, such as having bowel movements = 3 times a day; (3) Patients who have previously received or planned kidney transplantation in the past 6 months; (4) Peritoneal dialysis related Peritonitis occurred in the last month; (5) Receiving drugs or supplements that may affect the gut microbiota within the past month (such as antibiotics, probiotics, etc.; using chemical drugs to slow down diarrhea Agent and traditional Chinese patent medicines and simple preparations laxative without rhubarb); (6) Diagnosis of serious gastrointestinal diseases, including gastrointestinal bleeding, colitis, Inflammatory bowel disease, irritable bowel syndrome, Bowel obstruction History, history of Gastrectomy or duodenectomy; (7) Have a history of cardio cerebral Vascular disease in the past 3 months, and live due to stroke, myocardial infarction, unstable angina pectoris, congestive heart failure Hospital, severe valve stenosis, uncontrolled Atrial fibrillation and uncontrolled arrhythmia; (8) Concomitant with liver, hematopoietic system and other serious diseases, or known serious diseases that affect their survival (such as tumor or AIDS); (9) Researchers determine patients with a lifespan of = 6 months; (10) According to the evaluation of researchers, it is expected that gastrointestinal nutrition, special medical food treatment, or changing conventional dietary habits may be required within 6 months Patients; (11) Use Shenkang injection, Haikun Shenxi capsule, Shenshuening, Tripterygium wilfordii preparation, Niaoduqing granule, etc. to treat kidney disease in the last month Of traditional Chinese patent medicines and simple preparations patients; (12) Those who have participated in other intervention clinical trials within the past month; (13) Mentally or legally disabled patients; (14) Patients with intellectual disabilities, mental illness, or suspected or confirmed history of alcohol or drug abuse with poor compliance; (15) In addition to the above, the researchers have determined that patients who are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate of constipation treatment;Abundance and diversity of Gut microbiota;Changes in enterogenic uremic toxins; | — |
Secondary
| Measure | Time frame |
|---|---|
| Residual renal function;microinflammatory state;Degree of skin itching; | — |
Countries
China
Contacts
Public ContactLi Zuo
And Peking University People's Hospital
Outcome results
None listed